Director/PDMR Shareholding

10 March 2020 07:00 GMT

 

Transactions by Persons Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announced that, on 6 March 2020, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.

 

PDMR Ordinary Shares granted under the AZDBP Ordinary Shares granted under the AZPSP Award price per Ordinary Share
Pascal Soriot 8,734 87,346 £73.76
Marc Dunoyer 4,323 41,501 £73.76

 

The AZDBP award represents the portion of each PDMR's annual bonus for 2019 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.

 

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2020 to 31 December 2022). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.

 

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2019, which is available on the Company's website at www.astrazeneca.com/annualreport2019.

 

1   Details of the person discharging managerial responsibilities / person closely associated  
a)   Name     Pascal Soriot
2   Reason for the notification  
a)   Position/status     Chief Executive Officer
b)   Initial notification /Amendment     Initial notification
3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
a)   Name     AstraZeneca PLC
b)   LEI     PY6ZZQWO2IZFZC3IOL08
4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted    
a)   Description of the financial instrument, type of instrument   Identification code     Ordinary Shares of US$0.25 each in AstraZeneca PLC     GB0009895292  
b)   Nature of the transaction     Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan
c)   Price(s) and volume(s)      
Price(s)   Volume(s)
£73.76 96,080
   
d)   Aggregated information     - Aggregated volume     - Price     Not applicable - single transaction      
e)   Date of the transaction     6 March 2020
f)   Place of the transaction     Outside a trading venue

 

1   Details of the person discharging managerial responsibilities / person closely associated  
a)   Name     Marc Dunoyer
2   Reason for the notification  
a)   Position/status     Chief Financial Officer
b)   Initial notification /Amendment     Initial notification
3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
a)   Name     AstraZeneca PLC
b)   LEI     PY6ZZQWO2IZFZC3IOL08
4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted    
a)   Description of the financial instrument, type of instrument   Identification code     Ordinary Shares of US$0.25 each in AstraZeneca PLC     GB0009895292  
b)   Nature of the transaction     Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan
c)   Price(s) and volume(s)      
Price(s)   Volume(s)
£73.76 45,824
   
d)   Aggregated information     - Aggregated volume     - Price     Not applicable - single transaction      
e)   Date of the transaction     6 March 2020
f)   Place of the transaction     Outside a trading venue

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Media Relations    
Gonzalo Viña   +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Angela Fiorin BioPharmaceuticals +44 1223 344 690
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations    
Thomas Kudsk Larsen   +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (Cardiovascular, Metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (Renal) Environmental, Social and Governance +44 203 749 5716
Josie Afolabi BioPharmaceuticals (Respiratory)   +44 203 749 5631
Tom Waldron Other medicines +44 7385 033 717
Craig Marks Finance Fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access Retail investors +44 203 749 5824
US toll-free   +1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Subscribe

Documents & Links